MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Appourchaux, Kevin ^a,b,c   Dokmak, Safi ^b,d,e   Resche Rigon, Matthieu ^f   Treton, Xavier ^b   Lapalus, Martine ^a,b,c   Gattolliat, Charles Henry ^a,b,c   Porchet, Emmanuelle ^a,b,c   Martinot Peignoux, Michelle ^a,b,c   Boyer, Nathalie ^a,b,c   Vidaud, Michel ^f   Bedossa, Pierre ^b   Marcellin, Patrick ^a,b,c   Bièche, Ivan ^a   Estrabaud, Emilie ^a,b,c   Asselah, Tarik ^a,b,c  

^a INSERM   (France)

^b BEAUJON HOSPITAL   (France)

^c Laboratory of Excellence Labex INFLAMEX   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMINOID; MICRORNA;

ADULT; AREA UNDER THE CURVE; BIOPSY; BLOOD; BODY MASS; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COHORT ANALYSIS; COMPLICATION; FEMALE; FIBROSIS; GENETICS; HUMAN; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PLATELET COUNT; PROGNOSIS;

ADULT; ALANINE TRANSAMINASE; ALBUMINS; AREA UNDER CURVE; BIOPSY; BODY MASS INDEX; COHORT STUDIES; FEMALE; FIBROSIS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MICRORNAS; MIDDLE AGED; PLATELET COUNT; PROGNOSIS;

EID: 84991383726     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34935     Document Type: Article

References (60)

1. Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386, 1546-1555 (2015
2. De Martel, C., Maucort-Boulch, D., Plummer, M., & Franceschi, S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 62, 1190-1200 (2015
3. European Association for Study of, L. EASL. Recommendations on Treatment of Hepatitis C 2015. Journal of hepatology (2016
4. European Association For The Study Of The, L. EASL. Clinical practice guidelines: Management of chronic hepatitis B virus infection. Journal of hepatology 57, 167-185 (2012
5. Panel, A. I. H. G. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62, 932-954 (2015
6. Terrault, N A. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63, 261-283 (2016
7. Regev, A. et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. The American journal of gastroenterology 97, 2614-2618 (2002
8. Degos, F. et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). Journal of hepatology 53, 1013-1021 (2010
9. European Association for Study of, L., & Asociacion Latinoamericana para el Estudio del, H. EASL-ALEH. Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of hepatology 63, 237-264 (2015
10. Ray Kim, W. et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. Journal of hepatology 64, 773-780 (2016
11. Wai, C T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518-526 (2003
12. Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317-1325 (2006
13. Teshale, E. et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). Journal of viral hepatitis 21, 917-920 (2014
14. Xiao, G., Yang, J., & Yan, L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-Analysis. Hepatology 61, 292-302 (2015
15. in Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection (Geneva; 2014
16. in Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection (Geneva; 2015
17. Szabo, G., & Bala, S. MicroRNAs in liver disease. Nature reviews. Gastroenterology & hepatology 10, 542-552 (2013
18. Jin, B. X. et al. MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis. Scientific reports 5, 15026 (2015
19. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309, 1577-1581 (2005
20. Estrabaud, EE et Al. Reduction of MicroRNA 122 Expression in IFNL3 CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C. Journal of Virology 88, 6394-6402 (2014)
21. Chen, Y. et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 25, 4511-4521 (2011
22. Wang, S. et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology 55, 730-741 (2012
23. Marcellin, P., & Asselah, T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. Journal of gastroenterology and hepatology 28, 912-923 (2013
24. Martinot-Peignoux, M. et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51, 1122-1126 (2010
25. Bandiera, S., Pfeffer, S., Baumert, T. F., & Zeisel, M. B. miR-122-A key factor and therapeutic target in liver disease. Journal of hepatology 62, 448-457 (2015
26. Hsu, S. H. et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. The Journal of clinical investigation 122, 2871-2883 (2012
27. Ogawa, T. et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 61, 1600-1609 (2012
28. Jansen, F. et al. Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism. Journal of cellular and molecular medicine 19, 2202-2214 (2015
29. Hellerbrand, Wang, S. C., Tsukamoto, H., Brenner, D. A., & Rippe, R. A. Expression of intracellular adhesion molecule 1 by activated hepatic stellate cells. Hepatology 24, 670-676 (1996
30. Li, Y., Chen, Y., & Zhao, Y. The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-Analysis. PloS one 9, e105728 (2014
31. Mallet, V et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Alimentary pharmacology & therapeutics 29, 409-415 (2009
32. Kim, B. K. et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver international: official journal of the International Association for the Study of the Liver 30, 546-553 (2010
33. Fung, J. et al. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver international: official journal of the International Association for the Study of the Liver 28, 1408-1416 (2008
34. Seto, W K. et al. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PloS one 6, e23077 (2011
35. Gobel, T. et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. Journal of medical virology 83, 968-973 (2011
36. Lemoine, M. et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut 65, 1369-1376 (2016
37. Bedossa, P., & Carrat, F. Liver biopsy: the best, not the gold standard. Journal of hepatology 50, 1-3 (2009
38. Mehta, S. H., Lau, B., Afdhal, N. H., & Thomas, D. L. Exceeding the limits of liver histology markers. Journal of hepatology 50, 36-41 (2009
39. Calvaruso, V. et al. Computer-Assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49, 1236-1244 (2009
40. Zhang, D. Y. et al. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut 65, 1754-1764 (2016
41. Asselah, T Et Al. Liver Gene Expression Signature of Mild Fibrosis in Patients with Chronic Hepatitis C. Gastroenterology 129, 2064-2075 (2005
42. Trebicka, J. et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. Journal of hepatology 58, 234-239 (2013
43. Scisciani, C. et al. Transcriptional regulation of miR-224 upregulated in human HCCs by NFkappaB inflammatory pathways. Journal of hepatology 56, 855-861 (2012
44. Gao, P. et al. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-Associated multistep hepatocarcinogenesis. Journal of hepatology 54, 1177-1184 (2011
45. Lin, L., Lu, B., Yu, J., Liu, W., & Zhou, A. Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage. Clinics and research in hepatology and gastroenterology 40, 397-404 (2016
46. Bandiera, S. et al. HCV-induced up-regulation of miR-146a-5p in hepatocytes promotes viral infection and deregulates metabolic pathways associated with liver disease pathogenesis. Journal of virology 90, 6387-6400 (2016
47. Roderburg, C., & Luedde, T. Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. Journal of hepatology 61, 1434-1437 (2014
48. Liu, G. et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. The Journal of experimental medicine 207, 1589-1597 (2010
49. Chau, B. N. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Science translational medicine 4, 121ra118 (2012
50. Bedossa, P., & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24, 289-293 (1996
51. Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American journal of gastroenterology 94, 2467-2474 (1999
52. Vallet-Pichard, A., Mallet, V., & Pol, S. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. Hepatology 44, 769, author reply 769-770 (2006
53. Shrivastava, S. et al. Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 58, 863-871 (2013
54. Zhao, J. et al. MiR-21 simultaneously regulates ERK1 signaling in HSC activation and hepatocyte EMT in hepatic fibrosis. PloS one 9, e108005 (2014
55. Roderburg, C. et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53, 209-218 (2011
56. Du, J. et al. MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a. Scientific reports 5, 16163 (2015
57. Hou, J. et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer cell 19, 232-243 (2011
58. Ji, J. et al. MicroRNA expression, survival, and response to interferon in liver cancer. The New England journal of medicine 361, 1437-1447 (2009
59. Wong, Q W. et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1 Gastroenterology 135, 257-269 (2008
60. Estrabaud, E et al. IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C. PloS one 10, e0121395 (2015